Gene network analysis combined with preclinical studies to identify and elucidate the mechanism of action of novel irreversible Keap1 inhibitor for Parkinson’s disease-Reference-Cited by-同舟云学术

Gene network analysis combined with preclinical studies to identify and elucidate the mechanism of action of novel irreversible Keap1 inhibitor for Parkinson’s disease

Published:2024-08-15 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Arumugam Monisha,Pachamuthu Ranjith Sanjeeve,Rymbai Emdormi,Jha Aditya Prakash,Rajagopal Kalirajan,Kothandan Ram,Muthu Santhoshkumar,Selvaraj Divakar

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11030-024-10965-y.pdf

Reference66 articles.

1. Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, Zanette G, Tamburin S (2016) Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016:9832839. https://doi.org/10.1155/2016/9832839

2. Tang Y, Xiao X, Xie H, Wan CM, Meng L, Liu ZH, Liao WH, Tang BS, Guo JF (2017) Altered functional brain connectomes between sporadic and familial Parkinson’s patients. Front Neuroanat 11:99. https://doi.org/10.3389/fnana.2017.00099

3. Tran J, Anastacio H, Bardy C (2020) Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis 6:8. https://doi.org/10.1038/s41531-020-0110-8

4. Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:120–131. https://doi.org/10.1111/j.1749-6632.2003.tb07470.x

5. Lee J, Sung KW, Bae EJ, Yoon D, Kim D, Lee JS, Park DH, Park DY, Mun SR, Kwon SC, Kim HY, Min JO, Lee SJ, Suh YH, Kwon YT (2023) Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology. Mol Neurodegener 18(1):41. https://doi.org/10.1186/s13024-023-00630-7